Results of a pivotal Phase III trial of women with early and late-stage postmenopausal osteoporosis revealed that Amgen's denosumab significantly improved bone mineral density at the lumbar spine and total hip and wrist areas. The study tested the drug's efficacy as a twice-yearly subcutaneous injectable treatment.

Full Story:

Related Summaries